Peptipedia
CognitivePreclinicalAnimal Studies

P21

Also known as P021, Ac-DGGLAG-NH2

A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.

Preclinical - Development ongoing
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-15 mg daily

Frequency

Once daily

Duration

Ongoing supplementation in studies

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-15 mg daily via Oral (nasal in some studies), Once daily. Dose range: 10-15 mg daily. Duration: Ongoing supplementation in studies.

Timing & Administration

Administer via Oral (nasal in some studies). Frequency: Once daily.

Mechanism of Action

Acts as a CNTF small-molecule peptide mimetic, enhancing hippocampal neurogenesis, reducing tau phosphorylation, inhibiting neuroinflammation, and improving synaptic plasticity.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Development ongoing.

Side Effects & Safety

Important Warnings

  • Does not cause weight loss like native CNTF
  • Not FDA approved.
Injection site reactions
headache
fatigue

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
SemaxCognitive

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

View profile
CerebrolysinCognitive

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

View profile